FY2025 EPS Estimates for Humana Lifted by Cantor Fitzgerald

Key Points

• Analysts at Cantor Fitzgerald have raised their FY2025 EPS estimate for Humana to $17.02, up from a previous forecast of $16.32, while also rating the stock as "Neutral" with a target price of $290.00.
• Humana reported $6.27 EPS for its last quarter, missing estimates of $6.32 EPS, despite a 9.6% increase in quarterly revenue year-over-year to $32.39 billion.
• Humana's stock has seen a recent decline of 4.5%, with analysts assigning a consensus rating of "Hold" and an average target price of $281.62.

Humana Inc. (NYSE:HUM - Free Report) - Analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for shares of Humana in a research report issued on Thursday, July 31st. Cantor Fitzgerald analyst S. James now expects that the insurance provider will post earnings of $17.02 per share for the year, up from their prior forecast of $16.32. Cantor Fitzgerald currently has a "Neutral" rating and a $290.00 target price on the stock. The consensus estimate for Humana's current full-year earnings is $16.47 per share. Cantor Fitzgerald also issued estimates for Humana's FY2026 earnings at $13.86 EPS.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The business had revenue of $32.39 billion during the quarter, compared to analysts' expectations of $31.85 billion. During the same period in the previous year, the company posted $6.96 earnings per share. Humana's quarterly revenue was up 9.6% on a year-over-year basis.

HUM has been the topic of several other reports. Guggenheim began coverage on Humana in a research note on Wednesday, April 9th. They issued a "buy" rating and a $326.00 target price on the stock. Bank of America dropped their price objective on shares of Humana from $320.00 to $260.00 and set a "neutral" rating on the stock in a research note on Tuesday, June 17th. Raymond James Financial upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective for the company in a research report on Thursday, May 1st. Robert W. Baird lowered their target price on shares of Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a report on Friday, July 25th. Finally, Truist Financial cut their price target on shares of Humana from $280.00 to $260.00 and set a "hold" rating for the company in a report on Wednesday, July 16th. Sixteen analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Humana currently has a consensus rating of "Hold" and an average target price of $281.62.

Humana Stock Down 4.5%

HUM opened at $249.65 on Friday. Humana has a 52 week low of $206.87 and a 52 week high of $382.72. The business has a 50 day moving average price of $234.64 and a two-hundred day moving average price of $255.48. The company has a quick ratio of 1.91, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. The company has a market cap of $30.13 billion, a PE ratio of 19.16, a P/E/G ratio of 1.72 and a beta of 0.44.

Institutional Investors Weigh In On Humana

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of Humana by 8.9% in the first quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider's stock valued at $3,697,222,000 after purchasing an additional 1,143,662 shares in the last quarter. Dodge & Cox raised its position in shares of Humana by 5.5% during the 1st quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider's stock worth $2,845,830,000 after purchasing an additional 557,175 shares during the last quarter. Pzena Investment Management LLC lifted its stake in Humana by 6.5% in the 2nd quarter. Pzena Investment Management LLC now owns 4,076,667 shares of the insurance provider's stock valued at $996,664,000 after buying an additional 247,744 shares in the last quarter. Geode Capital Management LLC lifted its stake in Humana by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider's stock valued at $729,658,000 after buying an additional 63,562 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in Humana by 29.8% during the 4th quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider's stock valued at $608,348,000 after buying an additional 550,692 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.